Breaking Finance News

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Boasting a price of $17.39, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded -1.25% lower on the day. With the last stock price close up 48.94% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Vanda Pharmaceuticals Inc. has recorded a 50-day average of $15.70 and a two hundred day average of $11.69. Volume of trade was up over the average, with 861,756 shares of VNDA changing hands over the typical 818,388

Zacks Investment Research has downgraded Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Hold in a statement released on 10/11/2016.

Performance Chart

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

With a total market value of $0, Vanda Pharmaceuticals Inc. has with a one year low of $6.91 and a one year high of $18.00 .

Brief Synopsis About Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *